AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7884505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented 99mTc-labeled anti-CEA F(ab')2/Fab' fragment mixture F023C5
Number of subjects: 25
Study 7884505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both complete and fragmented MAbs
Number of subjects: 25
Study 7884505 — intervention group
Group type: COMPARATOR
Intervention: Complete MAbs
Number of subjects: 25
Study 7884505 — intervention group
Group type: COMPARATOR
Intervention: Fragmented MAbs
Number of subjects: 25
Study 2238753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 2238753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 552298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medigoxin (Lanitop) 300 microgram/day
Number of subjects: 0
Study 552298 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (Lanoxin) 500 microgram/day
Number of subjects: 0
Study 552298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medigoxin (Lanitop)
Number of subjects: 0
Study 552298 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (Lanoxin)
Number of subjects: 0
Study 30107414 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of HRQoL using the SF-6D questionnaire
Number of subjects: 1893
Study 30107414 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of HRQoL using SF-6D and SRH as an external standard
Number of subjects: 1893
Study 28178721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosaturation with percutaneous hepatic perfusion
Number of subjects: 91
Study 25331108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin 1 g daily for 3 days (group A)
Number of subjects: 218
Study 25331108 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (group B)
Number of subjects: 218
Study 23042303 — intervention group
Group type: EXPERIMENTAL
Intervention: High adiponectin levels (Quartile 4)
Number of subjects: 546
Study 23042303 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 546
Study 23042303 — intervention group
Group type: COMPARATOR
Intervention: Leptin
Number of subjects: 546
Study 23042303 — intervention group
Group type: COMPARATOR
Intervention: Resistin
Number of subjects: 546
Study 21488717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 0
Study 21488717 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 0
Study 18377756 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional open repair
Number of subjects: 259
Study 18377756 — intervention group
Group type: EXPERIMENTAL
Intervention: Expertise-based RCT methodology
Number of subjects: 259
Study 18377756 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional RCT design
Number of subjects: 259
Study 16701182 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 paravertebral injections
Number of subjects: 69
Study 16701182 — intervention group
Group type: COMPARATOR
Intervention: 1 paravertebral injection
Number of subjects: 69
Study 12950041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20
Study 12950041 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 10607686 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating Dose Regimen (EDR)
Number of subjects: 48
Study 10607686 — intervention group
Group type: COMPARATOR
Intervention: Bulk Dose Regimen (BDR)
Number of subjects: 48
Study 9177597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (walking three times a week for three months)
Number of subjects: 40
Study 9177597 — intervention group
Group type: COMPARATOR
Intervention: Control group (performing mental tasks with the same regularity)
Number of subjects: 40
Study 9177597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 40
Study 8274123 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic adhesive drape (drape group, n = 65)
Number of subjects: 120
Study 8274123 — intervention group
Group type: COMPARATOR
Intervention: No drape (no drape group, n = 55)
Number of subjects: 120
Study 8274123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 3328638 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work intervention
Number of subjects: 80
Study 3328638 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment by GPs (Control)
Number of subjects: 80
Study 31023487 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐chain omega-3 polyunsaturated fatty acids (LCn‐3PUFA) status (EPA + DHA, %,w/w)
Number of subjects: 2092
Study 31023487 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA levels in overweight/obese females with diabetes
Number of subjects: 2092
Study 31023487 — intervention group
Group type: EXPERIMENTAL
Intervention: LCn‐3PUFA status
Number of subjects: 2092
Study 30101519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (NAFL) treatment, 1540-nm, 40-50 mJ per microbeam, applied three times: immediately before surgery, at suture removal, and 6 weeks after surgery.
Number of subjects: 32
Study 30101519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment).
Number of subjects: 32
Study 27871563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) with 30 mL of 0.375% ropivacaine
Number of subjects: 60
Study 27871563 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (IVF) at 0.5 μg/kg body weight, repeated up to a maximum of 3 doses
Number of subjects: 60
Study 23712823 — intervention group
Group type: EXPERIMENTAL
Intervention: VPT/CEM
Number of subjects: 407
Study 23712823 — intervention group
Group type: COMPARATOR
Intervention: RCT
Number of subjects: 407
Study 22541747 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg tablet formulation (test product)
Number of subjects: 72
Study 20460711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (acetic acid)
Number of subjects: 0
Study 20460711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18387728 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser (30 mW for 1 min)
Number of subjects: 70
Study 18387728 — intervention group
Group type: COMPARATOR
Intervention: Dentin bonding agent
Number of subjects: 70
Study 15755827 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with low phytate/low isoflavone (LP/LI)
Number of subjects: 55
Study 15755827 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with normal phytate/low isoflavone (NP/LI)
Number of subjects: 55
Study 15755827 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with low phytate/normal isoflavone (LP/NI)
Number of subjects: 55
Study 15755827 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with normal phytate/normal isoflavone (NP/NI)
Number of subjects: 55
Study 15755827 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 55
Study 12960540 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to command during deep sedation with propofol and alfentanil
Number of subjects: 56
Study 12960540 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic monitoring (Bispectral Index)
Number of subjects: 56
Study 12960540 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate and responsiveness to command
Number of subjects: 56
Study 10553738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day
Number of subjects: 50
Study 10553738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/day
Number of subjects: 50
Study 10553738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/day
Number of subjects: 50
Study 10553738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 900 mg/day
Number of subjects: 50
Study 10553738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day (Gender effect)
Number of subjects: 50
Study 10553738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (all doses)
Number of subjects: 50
Study 8889424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 50
Study 8889424 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 50
Study 1802434 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 28
Study 1802434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6240223 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg) twice daily for 10 days
Number of subjects: 43
Study 6240223 — intervention group
Group type: COMPARATOR
Intervention: trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days
Number of subjects: 43
Study 6240223 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin
Number of subjects: 43
Study 6240223 — intervention group
Group type: COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Number of subjects: 43
Study 6240223 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin and trimethoprim-sulfamethoxazole
Number of subjects: 43
Study 30833118 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led physical activity program (4 days/week for 24 weeks, sessions lasting 25-45+ minutes)
Number of subjects: 111
Study 30833118 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led physical activity program (for those who increased MVPA)
Number of subjects: 111
Study 30833118 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 111
Study 29743826 — intervention group
Group type: EXPERIMENTAL
Intervention: bilberry juice (BJ)
Number of subjects: 21
Study 29743826 — intervention group
Group type: COMPARATOR
Intervention: energy‐matched control drink (PLA)
Number of subjects: 21
Study 26845343 — intervention group
Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol acetate 150 μg/mometasone furoate 320 μg)
Number of subjects: 0
Study 26845343 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol monotherapy
Number of subjects: 0
Study 26845343 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate monotherapy
Number of subjects: 0
Study 24740596 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 6026
Study 24740596 — intervention group
Group type: COMPARATOR
Intervention: Al(OH)3 control
Number of subjects: 6026
Study 23036993 — intervention group
Group type: EXPERIMENTAL
Intervention: LoGIx diet
Number of subjects: 21
Study 23036993 — intervention group
Group type: EXPERIMENTAL
Intervention: HiGIx diet
Number of subjects: 21
Study 19950740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV) with PEEP of 5cm H2O
Number of subjects: 90
Study 19950740 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Respiration (SR)
Number of subjects: 90
Study 18457257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) applied topically, 9000 AU NGF in 100 ml saline solution before operation and injections every other day for one month post-operation
Number of subjects: 48
Study 18457257 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with normal saline solution
Number of subjects: 48
Study 15368601 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (recombinant human growth hormone)
Number of subjects: 51
Study 15368601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11248285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg subcutaneous administration
Number of subjects: 30
Study 11248285 — intervention group
Group type: COMPARATOR
Intervention: Tinzaparin-like LMWH
Number of subjects: 30
Study 11248285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin and Tinzaparin-like LMWH
Number of subjects: 30
Study 9831696 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine (20-40 mg once daily)
Number of subjects: 48
Study 9831696 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (10-20 mg once daily)
Number of subjects: 48
Study 9831696 — intervention group
Group type: COMPARATOR
Intervention: control group (normotensive healthy subjects)
Number of subjects: 48
Study 9831696 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine and lisinopril (compared to each other)
Number of subjects: 48
Study 7990347 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukinferon administered intramuscularly for 10 days (day 1: 3 samples, day 2: 2 ampules, day 3: 1 ampule daily, total 1 x 10(5) U of interferon)
Number of subjects: 30
Study 2524327 — intervention group
Group type: EXPERIMENTAL
Intervention: netilmicin 200 mg daily
Number of subjects: 30
Study 2524327 — intervention group
Group type: EXPERIMENTAL
Intervention: netilmicin 200 mg + ampicillin 1 g daily
Number of subjects: 30
Study 31918668 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal intercostal block (n = 32)
Number of subjects: 20
Study 31918668 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block (n = 26)
Number of subjects: 20
Study 31918668 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal intercostal block
Number of subjects: 20
Study 31918668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Proximal intercostal and Paravertebral blocks)
Number of subjects: 20
Study 29703044 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 40
Study 29703044 — intervention group
Group type: COMPARATOR
Intervention: Deroofing
Number of subjects: 40
Study 28377023 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ultrasound-guided rectus sheath block (PERC)
Number of subjects: 58
Study 28377023 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative rectus sheath block (IO)
Number of subjects: 58
Study 25838206 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D
Number of subjects: 776
Study 23541643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level I: 69 Gy in 30 fractions of 2.3 Gy
Number of subjects: 57
Study 23541643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level II: 72 Gy in 30 fractions of 2.4 Gy
Number of subjects: 57
Study 23541643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level III: 75 Gy in 30 fractions of 2.5 Gy
Number of subjects: 57
Study 23541643 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 57
Study 22014101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 100,000 IU every 4 weeks
Number of subjects: 120
Study 22014101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19495544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (2.5 mg) three times per day
Number of subjects: 73
Study 19495544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal electric stimulation
Number of subjects: 73
Study 19495544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16923001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 98
Study 16923001 — intervention group
Group type: COMPARATOR
Intervention: Cephalic venotomy technique
Number of subjects: 98
Study 15181050 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone 50 mg/d
Number of subjects: 397
Study 15181050 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone 100 mg/d
Number of subjects: 397
Study 15181050 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone 200 mg/d
Number of subjects: 397
Study 15181050 — intervention group
Group type: COMPARATOR
Intervention: nonresponders
Number of subjects: 397
Study 15181050 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone (all doses)
Number of subjects: 397
Study 11230886 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT+EBB (External irradiation plus endobronchial brachytherapy)
Number of subjects: 95
Study 11230886 — intervention group
Group type: COMPARATOR
Intervention: XRT (External irradiation alone)
Number of subjects: 95
Study 9027779 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily, n = 24)
Number of subjects: 53
Study 9027779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 53
Study 8391513 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 42495 (200 mg, every 12 hours)
Number of subjects: 8
Study 3090614 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of scout films
Number of subjects: 1001
Study 3090614 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective use of scout films
Number of subjects: 1001
Study 30113538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 66
Study 30113538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 66
Study 30113538 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 66
Study 27259970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.
Number of subjects: 24
Study 27259970 — intervention group
Group type: COMPARATOR
Intervention: Sodium naproxen 550 mg b.i.d. plus placebo
Number of subjects: 24
Study 24667035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium salt substitute
Number of subjects: 0
Study 24667035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the implementation strategy
Number of subjects: 0
Study 22697333 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (HT)
Number of subjects: 12
Study 22697333 — intervention group
Group type: COMPARATOR
Intervention: Step‐and‐shoot IMRT
Number of subjects: 12
Study 20142308 — intervention group
Group type: EXPERIMENTAL
Intervention: R213129 3 mg
Number of subjects: 45
Study 20142308 — intervention group
Group type: EXPERIMENTAL
Intervention: R213129 10 mg
Number of subjects: 45
Study 20142308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18052708 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) graft and coronally positioned flap (CPF)
Number of subjects: 14
Study 18052708 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap (CPF) alone
Number of subjects: 14
Study 15763574 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (24 g ethyl alcohol, 1508 kJ, 405 ml)
Number of subjects: 12
Study 15763574 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol (867 kJ, 405 ml)
Number of subjects: 12
Study 12046033 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg/d for 8 weeks
Number of subjects: 62
Study 12046033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 11783153 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin (600 mg intravenously, once daily for one week)
Number of subjects: 48
Study 11783153 — intervention group
Group type: COMPARATOR
Intervention: Control (same treatment as treated group, but without puerarin)
Number of subjects: 48
Study 7825526 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet rich in monounsaturated fatty acids (MUFA) for 12 weeks
Number of subjects: 122
Study 2109445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 120 mg orally one hour prior to GHRH (100 micrograms iv)
Number of subjects: 12
Study 2109445 — intervention group
Group type: COMPARATOR
Intervention: GHRH (100 micrograms iv) alone
Number of subjects: 12
Study 2109445 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms iv) with pyridostigmine (120 mg)
Number of subjects: 12
Study 2109445 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (higher doses) or pyridostigmine (higher doses)
Number of subjects: 12
Study 396673 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinase (thrombolytic enzyme)
Number of subjects: 27
Study 396673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 27
Study 30146268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (LUM/IVA) 400 mg q12h / 250 mg q12h
Number of subjects: 369
Study 27405732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment (CMT)
Number of subjects: 239
Study 27405732 — intervention group
Group type: COMPARATOR
Intervention: Subtotal lymphoid irradiation (STLI)
Number of subjects: 239
Study 23692587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose paracetamol (6 grams daily for three consecutive days)
Number of subjects: 1500
Study 23692587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for three consecutive days)
Number of subjects: 1500
Study 23545371 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD diagnosis with no effectiveness information
Number of subjects: 0
Study 23545371 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD diagnosis with effectiveness information
Number of subjects: 0
Study 23545371 — intervention group
Group type: COMPARATOR
Intervention: No disease label with no effectiveness information
Number of subjects: 0
Study 23545371 — intervention group
Group type: COMPARATOR
Intervention: No disease label with effectiveness information
Number of subjects: 0
Study 21953763 — intervention group
Group type: EXPERIMENTAL
Intervention: HDLI (higher demand dose with low constant infusion)
Number of subjects: 38
Study 21953763 — intervention group
Group type: COMPARATOR
Intervention: LDHI (lower demand dose and higher constant infusion)
Number of subjects: 38
Study 21953763 — intervention group
Group type: EXPERIMENTAL
Intervention: HDLI
Number of subjects: 38
Study 21953763 — intervention group
Group type: COMPARATOR
Intervention: LDHI
Number of subjects: 38
Study 18187214 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg/day
Number of subjects: 24
Study 18187214 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (Control)
Number of subjects: 24
Study 17563167 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 97
Study 17563167 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered supportive emotion focused therapy (T-SEFT)
Number of subjects: 97
Study 15845678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia at concentrations of 0.7%, 1.4%, and 2.0%
Number of subjects: 9